J&J Independence iBOT Stair-Climbing Data Need Scrutiny, FDA Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Independence Technology should prospectively evaluate user training for the Independence iBOT 3000 Advanced Mobility System specific to stair-climbing at home and test sites, FDA's Orthopaedic & Rehabilitation Devices Panel recommended Nov. 20 in Gaithersburg, Maryland
You may also be interested in...
J&J’s iBOT Wins Expedited FDA Approval, Faces Reimbursement Roadblocks
FDA will evaluate the need for labeling revisions to Johnson & Johnson/Independence Technology's iBOT 3000 stair-climbing wheelchair upon receipt of four semi-annual reports from the company
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”